Enhancing Outcomes and Reducing Treatment Burden with Advanced Therapies in Neovascular AMD and DME : Episode 3

Treat-and-Extend Strategy With Aflibercept

January 3, 2025

By John Kitchens, MD
Richard Gale, PhD, MEd, BSc, MBChB, FRCP, FRCOphth

Opinion

Video

Panelists discuss how treat-and-extend dosing with aflibercept 2 mg allows for individualized treatment intervals while maintaining vision gains. However, optimal extension timing must be carefully determined based on disease activity markers.

EP: 1.Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

EP: 2.Advantages of the molecular structure of aflibercept

Now Viewing

EP: 3.Treat-and-Extend Strategy With Aflibercept

EP: 4.Assessing New Therapies for Retinal Diseases

EP: 5.Significance of the Higher Molar Dose of Aflibercept 8 mg

EP: 6.Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

EP: 7.Patient Selection for Aflibercept 8 mg

EP: 8.Faricimab Molecular Design and Role of Ang-2

EP: 9.Outcomes with Faricimab and Choosing Between the New Therapies

EP: 10.Safety Profile of New Therapies

EP: 11.Perspectives on the Usefulness of Real-world Data

EP: 12.Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

EP: 13.Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

Video content above is prompted by the following:

What has been your experience using the treat-and-extend strategy with aflibercept 2 mg?

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Subscribe Now!